Recce Pharmaceuticals

Recce Pharmaceuticals Pre-Tax Margin

The Pre-Tax Profit Margin of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is -285.37 %. In the previous year, Pre-Tax Profit Margin was -448.81 % — a change of -36.42% (higher).

Pre-Tax Margin

-285.37 %

YoY

-36.42%

Last updated:

Pre-Tax Profit Margin of Recce Pharmaceuticals is 2025 -285.37 % . Pre-Tax Profit Margin of Recce Pharmaceuticals was 2024 -448.81 % . It decreases by -36.42% higher compared to the previous year.

The Recce Pharmaceuticals Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-229.94 AUD
Jan 1, 2019
-510.40 AUD
Jan 1, 2020
-480.37 AUD
Jan 1, 2021
-920.95 AUD
Jan 1, 2022
-456.12 AUD
Jan 1, 2023
-398.35 AUD
Jan 1, 2024
-448.81 AUD
Jan 1, 2025
-285.37 AUD
The Recce Pharmaceuticals Pre-Tax Margin history
YEARPre-Tax MarginYoY
-285.37 %-36.42%
-448.81 %+12.67%
-398.35 %-12.67%
-456.12 %-50.47%
-920.95 %+91.72%
-480.37 %-5.88%
-510.40 %+121.97%
-229.94 %-89.88%
-2,272.01 %-19.13%
-2,809.44 %+610.55%
-395.39 %+40.99%
-280.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Pre-Tax Profit Margin of Recce Pharmaceuticals is -285.37 % in 2025.

Pre-Tax Profit Margin of Recce Pharmaceuticals changed from -448.81 % to -285.37 %, representing a -36.42% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals